双相障碍脑锂时空动力学:德国7Li MRI重复测量研究
该研究在德国4家精神科门诊招募41名双相障碍心境平稳期患者,比较每日一次与每日两次碳酸锂给药方案下脑锂7Li MRI信号与血锂浓度的日内变化。结果显示脑锂信号紧密跟随各自方案的血锂曲线,但在标准给药后12小时采样点两方案趋于一致;白质脑锂信号高于灰质,灰质平衡快于脑脊液和白质。
要点
- 脑锂浓度日内变化紧密跟随血锂浓度,但每日一次与每日两次方案在给药后12小时采样点趋于一致。
- 两方案下白质脑锂MRI信号均高于灰质,灰质平衡速度快于脑脊液和白质。
- 上述脑与血锂曲线的方案差异可为临床给药方案选择与治疗药物监测策略提供参考。
核心结论
- 脑锂浓度在一天中紧密跟随血锂浓度变化,但在标准给药后12小时采样时间点两方案趋于一致。
- 每日一次与每日两次给药下脑与血锂曲线的差异可为临床给药方案选择和治疗监测策略提供信息。
研究设计与样本
- 重复测量横断面影像学研究,在德国德累斯顿4家精神科门诊招募18-50岁双相I型或II型心境平稳期患者。
- 41名受试者接受稳定碳酸锂治疗,其中每日一次组20人、每日两次组21人。
- 核心评估为1天方案:在10小时内(0800、1400、1800)连续进行3次7Li MRI扫描并同步采血。
主要发现
- 在给药后12小时(0800),两方案间脑7Li MRI信号强度与血锂浓度相当。
- 每日一次组血锂浓度全天下降;每日两次组晨服后血锂升高随后下降,脑7Li MRI信号紧密对应各自血锂曲线。
- 两方案下白质脑7Li MRI信号强度均高于灰质,脑-血比值提示灰质平衡速度快于脑脊液和白质。
关键数值与推荐
- 共筛查并纳入44名合格受试者,其中3人在评估前退出,最终评估41人。
- 评估前一周给药时间为2000时(每日一次全量或每日两次的晚间剂量)和0800时(仅每日两次方案)。
临床怎么用
- 提示解读血锂参考范围时需考虑给药方案与采样时间点,标准给药后12小时采样两方案脑锂趋于一致。
- 脑与血锂曲线的方案差异可辅助个体化选择每日一次或每日两次给药及治疗药物监测策略。
局限性
- 样本量较小(41人)且全部为欧洲白人,结果外推需谨慎。
- 为横断面重复测量设计,未涉及临床结局或疗效与脑锂水平的关联。
- 原文未报告盲法、随机化及长期随访信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lithium remains a first-line treatment for bipolar disorder, but practice varies regarding dosing frequency. Although once-daily and twice-daily regimens are similarly effective, they produce serum lithium profiles that differ over the day, and whether greater fluctuations with once-daily dosing are attenuated in the brain is unclear. The aim of this study was to evaluate whether brain lithium profiles differed across the day with once-daily versus twice-daily dosing regimens. METHODS: In this repeated-measures, cross-sectional imaging study, euthymic individuals (aged 18-50 years) with bipolar disorder type I or II receiving stable lithium carbonate treatment were recruited at four psychiatric outpatient departments in Dresden, Germany. In the week before assessment, participants received lithium at 2000 h (full once-daily dose or evening dose of the twice-daily regimen) and 0800 (twice-daily regimen only; withheld until after the 0800 h sampling on assessment day). The core assessment was a 1-day protocol in which participants underwent three consecutive 7Li MRI scans and matched serum sampling over a 10-h period (0800, 1400, and 1800h). Whole-brain lithium measurements across timepoints were compared according to regimen using the brain observable lithium threshold region-of-interest approach. Secondary analyses modelled tissue-specific profiles, derived from the Newcastle lithium image voxel evaluation pipeline, and examined the relationship between serum lithium concentration and brain 7Li MRI signal intensity using repeated-measures ANOVA, linear mixed-effects models, and population pharmacokinetics. This study was informed by people with lived experience of bipolar disorder and long-term lithium treatment through patient and public involvement and engagement activities. FINDINGS: Between April 19, 2022, and Dec 9, 2023, 44 eligible participants were recruited, of whom three withdrew before assessment. Therefore, 41 euthymic individuals (all White European; 21 [51%] female and 20 [49%] male; mean age 39·2 years [SD 9·8]) with bipolar disorder receiving stable lithium carbonate treatment (20 in the once-daily dosing group and 21 in the twice-daily dosing group) were evaluated. At 12 h post dose (0800 h), brain 7Li MRI signal intensity and serum lithium concentrations were equivalent across regimens. In the once-daily group, serum lithium declined across the day, whereas in the twice-daily group it increased after the morning dose and then decreased. Brain 7Li MRI signal intensity closely mirrored these regimen-specific serum profiles. Brain 7Li MRI signal intensity was higher in white matter than grey matter in both regimens and brain-to-serum ratios indicated more rapid equilibration in grey matter compared with cerebrospinal fluid and white matter. INTERPRETATION: Brain lithium concentrations followed serum concentrations closely across the day but aligned between regimens at the standard 12-h post-dose sampling timepoint. These findings directly inform ongoing discussions about the applicability of a common reference range across regimens. The difference in brain and serum profiles of lithium with once-daily and twice-daily dosing might inform regimen selection and therapeutic monitoring strategies in clinical practice. FUNDING: Baszucki Brain Research Foundation and Deutsche Forschungsgemeinschaft (German Research Foundation).
引用
- Ritter P, Edelmann K, Thelwall PE, et al. Brain lithium temporospatial kinetics in bipolar disorder: a repeated-measures 7Li MRI study of dosing regimens in Germany. Lancet Psychiatry. 2026. PMID: 42365853. doi:10.1016/S2215-0366(26)00153-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。